- Home
- SBFM vs XRTX Comparison
SBFM vs XRTX Comparison
Compare SBFM & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- XRTX
- Stock Information
- Founded
- SBFM 2006
- XRTX 2011
- Country
- SBFM United States
- XRTX Canada
- Employees
- SBFM N/A
- XRTX N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- SBFM Health Care
- XRTX Health Care
- Exchange
- SBFM Nasdaq
- XRTX Nasdaq
- Market Cap
- SBFM 3.7M
- XRTX 4.1M
- IPO Year
- SBFM N/A
- XRTX N/A
- Fundamental
- Price
- SBFM $2.90
- XRTX $1.00
- Analyst Decision
- SBFM Strong Buy
- XRTX
- Analyst Count
- SBFM 1
- XRTX 0
- Target Price
- SBFM $15.00
- XRTX N/A
- AVG Volume (30 Days)
- SBFM 151.9K
- XRTX 278.9K
- Earning Date
- SBFM 11-05-2024
- XRTX 11-15-2024
- Dividend Yield
- SBFM N/A
- XRTX N/A
- EPS Growth
- SBFM N/A
- XRTX N/A
- EPS
- SBFM N/A
- XRTX N/A
- Revenue
- SBFM $32,959,491.00
- XRTX N/A
- Revenue This Year
- SBFM $59.94
- XRTX N/A
- Revenue Next Year
- SBFM $164.69
- XRTX N/A
- P/E Ratio
- SBFM N/A
- XRTX N/A
- Revenue Growth
- SBFM 61.94
- XRTX N/A
- 52 Week Low
- SBFM $2.11
- XRTX $0.85
- 52 Week High
- SBFM $572.00
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- SBFM 49.22
- XRTX 36.68
- Support Level
- SBFM $2.79
- XRTX $0.85
- Resistance Level
- SBFM $2.94
- XRTX $1.79
- Average True Range (ATR)
- SBFM 0.26
- XRTX 0.19
- MACD
- SBFM -0.03
- XRTX -0.01
- Stochastic Oscillator
- SBFM 16.70
- XRTX 15.76
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.